BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases, today announces the appointment of Jean-Luc Vandebroek as Chief Financial Officer, effective 1 September 2017. Jean-Luc will replace Wim Goemaere, who is leaving the Company to take up a senior position within a not-for-profit organisation. Wim will continue to support the Company as a Non-Executive Director, and will lead a managed succession during the transition period.
Jean-Luc Vandebroek is a seasoned finance executive with extensive international finance experience at major public and privately-owned companies. Jean-Luc has built a successful career spanning 15 years at the Belgian-US retailer, Delhaize Group (now Ahold Delhaize). During this period, he held various senior financial positions with increasing responsibility, including roles as Corporate Director Finance Europe and US and Vice President Finance BeLux. He later became Group Chief Financial Officer at Fluxys, a listed, pan-European gas infrastructure group, where he was responsible for the financing of large infrastructure investments using diverse forms of funding on capital markets. Prior to joining Bone Therapeutics, Jean-Luc served as Director and Chief Financial Officer of Moteo Two Wheels and Bihr Europe, the motorcycle division of Alcopa Group, a Belgian family holding with an annual revenue of around EUR 1.7 billion.
Steve Swinson, Chairman of Bone Therapeutics, commented:
"We are pleased to welcome Jean-Luc Vandebroek to Bone Therapeutics. With his strong financial acumen, experience leading commercial-stage companies and understanding of corporate finance, Jean-Luc is well equipped to oversee Bone Therapeutics’ financial planning needs in its increasingly mature phase of development. The Board wishes to express its gratitude to Wim Goemaere for his significant contribution to the development of Bone Therapeutics, including stewarding the Company through a successful initial public offering in 2015 which raised EUR 37 million. We are glad that he will continue to support the Board of Bone Therapeutics as a Non-Executive Director and wish him well in his new role."
Commenting on his appointment, Jean-Luc Vandebroek said:
“I am delighted to be joining Bone Therapeutics at this exciting time in its development. I look forward to working with the Board and management team to help deliver value to shareholders and bring Bone Therapeutics’ innovative cell therapy products closer to the market and to patients.”
Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.